Navigation Links
Synthetic Biologics to Present at the 7th Annual OneMedForum San Francisco 2014 Conference
Date:1/8/2014

ROCKVILLE, Md., Jan. 8, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 7th Annual OneMedForum San Francisco 2014 conference next week in San Francisco, as follows:

Date: Tuesday, January 14, 2014
Time: 11:30 a.m. (PT)/2:30 p.m. (ET)
Location: The Westin San Francisco Market Street Hotel

A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the internet at http://onemedplace.com/forum/webcast/. After the presentation, a replay will be archived and accessible for 30 days at the same website.

(Logo: http://photos.prnewswire.com/prnh/20130522/MM19465LOGO)

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of product candidates for serious infectious and other diseases. Synthetic Biologics is developing oral treatments targeting archaea, a non-bacterial intestinal form of life increasingly associated with chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes, an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of C. diff infection, a series of monoclonal antibodies (mAbs) for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of IBS. In addition, the Company is developing an oral estriol drug candidate for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS (with results of an ongoing 164 subject, 15 center, two-year, double blind, placebo controlled, Phase II relapsing-remitting MS clinical trial expected to be announced during the first half of 2014). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Green Dot Develops Compostable Synthetic Leather Made with its Terratek® Flex Bioplastic
2. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
3. Synthetic Biologics Announces Proposed Public Offering of Common Stock
4. Global Geosynthetics Market 2012-2016
5. Process holds promise for production of synthetic gasoline
6. Startup to Strengthen Synthetic Biology and Regenerative Medicine Industries with Cutting Edge Cell Products
7. Advancements in High-Speed DNA Synthesis to Drive Growth in the Global Synthetic Biology Market, According to New Report by Global Industry Analysts, Inc.
8. Synthetic Biologics SYN-004 for the Prevention of C. difficile Infections Named a "Top Project to Watch" by Elsevier Business Intelligence
9. Synthetic Biologics Reports Third Quarter 2013 Financial Results and Operational Update
10. China Synthetic Resin Industry Report, 2013-2016
11. Synthetic Biologics to Report Third Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  SeraCare Life ... global in vitro diagnostics manufacturers and clinical ... industry,s first multiplexed Inherited Cancer reference ... by next-generation sequencing (NGS). The Seraseq™ Inherited ... with input from industry experts to validate ...
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
(Date:3/22/2017)... March 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), ... Center (RGC), U.K. Biobank and GSK to generate genetic sequence ... resource. The initiative will enable researchers to gain valuable insights ... a wide range of serious and life threatening diseases. ... Genetic evidence ...
(Date:3/22/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... ), a clinical-stage pharmaceutical company focused on the ... that Dr. Miriam Kidron , Oramed,s Chief ... Insulin for Diabetes Treatment: Bypassing the Roadblock," at ... Therapeutics (OPT) Boston Conference in Cambridge, Massachusetts ...
Breaking Biology Technology:
(Date:2/28/2017)...  EyeLock LLC, ein marktführendes Unternehmen im Bereich ... Lösung zur Iris-Erkennung auf der neuesten Mobilplattform ... dem Mobile World Congress 2017 (27. Februar ... 3, Stand 3E10, vorstellen. Der ... – eine Kombination aus Hardware, Software und ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
Breaking Biology News(10 mins):